HUINNO
HUINNO is a South Korea-based digital health company that combines FDA-cleared wearable ECG devices with AI-based arrhythmia detection algorithms to deliver continuous cardiac monitoring for hospitals and cardiology departments, serving both in-patient telemetry and ambulatory monitoring use cases.
- Company typePrivate
- Founded2014
- HeadquartersSeoul, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What HUINNO does
HUINNO is a South Korea-based digital health company founded in 2014 that combines FDA-cleared wearable biosignal monitoring hardware with proprietary AI-based analytics to enable continuous cardiac monitoring and arrhythmia detection in both hospital and ambulatory settings. Its core platform comprises MEMO Cue, an in-hospital telemetry solution supporting up to 300 simultaneous patients via web-based monitoring on Cloud or On-Premise deployments, and MEMO Care, an ambulatory ECG monitoring solution extending continuous monitoring up to 14 days versus the standard 24-48 hour Holter window. Supporting hardware includes MEMO Patch M (FDA 510(k)-cleared, 12g, 8-day battery, defibrillation-protected), MEMO Patch 2 (IP27-rated, 14-day monitoring, iF and Red Dot Design Award winner), MEMO Band (MFDS-approved pulse oximeter), and MEMO Watch (CE-certified wrist-type multi-biosignal device). The proprietary MEMO AI engine powers bit-level deep-learning ECG segmentation and arrhythmia classification, ranked 1st globally in 4-lead and 6-lead categories at the PhysioNet AI Challenge 2021 and clinically validated at major Korean university hospitals with an 89% improvement in arrhythmia detection vs. traditional Holter monitoring.
The company operates a hybrid revenue model spanning hardware sales of wearable ECG devices to hospitals, SaaS subscriptions for MEMO Cue and MEMO Care monitoring platforms, and licensing/distribution arrangements including domestic Korean rights held by Yuhan Corporation and US market entry via Yuhan USA (announced March 2026). The recent acquisition of Korean National Health Insurance reimbursement code EX871 (March 2025) for remote heartbeat monitoring marks a transition toward recurring reimbursement-based revenue. HUINNO serves hospitals and cardiology departments as primary customers (H Plus Yangji Hospital being the first commercial MEMO Cue deployment covering ~100 beds), with secondary expansion targets including the US healthcare market and broader patient monitoring applications in general wards beyond ICU. The company has raised approximately $60M+ cumulatively across multiple funding rounds from 2019-2022, is backed by strategic investor Yuhan Corporation alongside financial investors including Smilegate Investment, Woori Venture Partners, and FuturePlay, and operates a subsidiary structure including wholly-owned Huinno AIM and the KHAIM joint venture with Korea University Medical Technology Holdings.
HUINNO firmographics
Firmographics- Name
- HUINNO
- Legal name
- 주식회사 휴이노 (Huinno Co., Ltd.)
- Website
- https://huinno.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- HUINNO is a South Korea-based digital health company that combines FDA-cleared wearable ECG devices with AI-based arrhythmia detection algorithms to deliver continuous cardiac monitoring for hospitals and cardiology departments, serving both in-patient telemetry and ambulatory monitoring use cases.
- Ownership category
- akta.pro rank
HUINNO industry classification
Industry- Product category
- Cardiac Monitoring Solutions
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)
- akta.pro secondary industries
- Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), ECG/EKG & Heart Rhythm Monitors (Consumer) (CRACAQAC), Pulse Oximeters & Respiratory Monitors (Consumer) (CRACAQAF), Cardiology Telemedicine Platforms (HLALAGAB)
Keywords
Where HUINNO is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
HUINNO business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Wearable Medical Device Sales: Sales of wearable ECG monitoring devices including MEMO Patch M, MEMO Patch 2, and MEMO Watch. Devices are sold to hospitals and healthcare providers for patient monitoring.
- Software as a Service (SaaS) - Remote Patient Monitoring: Cloud-based software subscriptions for MEMO Cue (in-patient telemetry) and MEMO Care (ambulatory ECG monitoring) platforms. The company received insurance reimbursement codes (보험수가) for remote heartbeat monitoring technology (EX871) in March 2025.
- Licensing and Distribution Agreements: Licensing agreements for MEMO Patch domestic rights (Yuhan Corporation) and potential international distribution partnerships.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels4 records
HUINNO product offering
Product offeringCore offering
HUINNO develops and sells AI-powered cardiac monitoring solutions that combine wearable biosignal sensors with cloud-based AI analytics to enable continuous in-hospital patient monitoring (MEMO Cue) and extended ambulatory ECG monitoring (MEMO Care). The integrated stack includes FDA 510(k)-cleared and CE-certified wearable ECG/respiration devices (MEMO Patch M, MEMO Patch 2, MEMO Watch, MEMO Band), web-based central monitoring and ECG analysis software, and an award-winning arrhythmia detection algorithm, sold primarily to hospitals and cardiology departments.
Product overview
HUINNO offers a dual-core product architecture centered on MEMO Cue (in-patient telemetry) and MEMO Care (ambulatory ECG monitoring), both powered by proprietary MEMO AI technology. The portfolio comprises two wearable ECG devices (MEMO Patch M for hospital monitoring, MEMO Patch 2 for extended ambulatory monitoring), supporting software platforms (MEMO Care Web for patient management, MEMO Report for ECG analysis, Medical Staff App for device control, MEMO for Desktop for data management), and mobile/portable solutions (MEMO Cue Mobile for hospital-wide monitoring). Recent additions include MEMO Band for oxygen saturation and MEMO Watch for multi-parameter vital signs. The system integrates with Samsung Galaxy devices and KakaoTalk chatbot for patient symptom tracking.
Differentiator
Problem solved
Functional benefit
Brands
- MEMO: Digital health platform brand featuring products including MEMO Patch (wearable ECG monitoring device) and MEMO Care solutions.
Products and services
- MEMO Cue In-hospital patient telemetry solution combining wearable ECG/respiration sensors (MEMO Patch M) with a web-based central monitoring software (MEMO Cue) and portable data transmission device (MEMO Cue Mobile), enabling 24-hour continuous cardiac monitoring beyond the ICU into general wards, multi-patient monitoring of up to 300 patients simultaneously, AI-based arrhythmia detection with 19 vital sign and 8 technical alarms, and Cloud or On-Premise deployment. Targeted at hospitals and healthcare systems for continuous inpatient cardiac monitoring.
- MEMO Care Ambulatory ECG monitoring solution using wearable devices (MEMO Patch 2) and big-data AI analysis to extend monitoring periods up to 14 days versus the 48-hour limit of standard Holter tests. Includes a web-based patient management system, ECG analysis and editing, automated report generation, and KakaoTalk chatbot integration for patient symptom and sleep logging. Targeted at cardiology departments and arrhythmia clinics for ambulatory arrhythmia diagnosis.
- MEMO Patch M Wearable ECG and respiration monitor for in-patient telemetry use within the MEMO Cue system; 12g weight, up to 8-day battery life, stable Bluetooth data transmission with disconnection alerts, defibrillation protection, and a user-friendly design that has won a Design Award. Designed for hospital in-patients requiring continuous cardiac and respiratory monitoring.
- MEMO Patch 2 Second-generation wearable ECG monitor for ambulatory monitoring within the MEMO Care solution; all-in-one integrated design with a 64% weight reduction and 75% volume reduction versus the prior model, IP27 water/dust resistance, and up to 14-day continuous ECG monitoring. Winner of the iF Design Award 2024 (2 categories) and Red Dot Design Award. Designed for ambulatory cardiac patients requiring extended monitoring.
- MEMO Watch Wrist-worn wearable multi-biosignal device measuring ECG, blood pressure, and oxygen saturation, developed using non-compressive non-invasive blood pressure estimation technology. Received CE certification in 2021 and was the first domestic wearable ECG device to be listed for Korean health insurance coverage by HIRA. Designed for continuous outpatient multi-parameter vital sign monitoring.
- MEMO Band Wearable pulse oximeter for oxygen saturation measurement; received MFDS (Korea Ministry of Food and Drug Safety) medical device category approval in May 2025. Designed for patients requiring continuous oxygen saturation monitoring alongside HUINNO's ECG monitoring portfolio.
Quantifiable outcome
- 89% higher arrhythmia detection rate compared to traditional 24-hour Holter monitoring
- +4 more outcomes
Companies that use HUINNO
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
HUINNO technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability5 records
Feature8 records
HUINNO partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Yuhan USAcoreHuinno partnered with Yuhan USA to enter the US digital healthcare market, focusing on AI-based cardiac monitoring solutions and launching a clinical prediction platform. The collaboration aims to develop sales, marketing, regulatory support, and logistics to accelerate market entry.
- Bucheon Sejong Hospital (부천세종병원)minorMOU signed for ECG analysis collaboration in February 2023 for research and clinical applications.
- Johnson & Johnson Medical Korea (한국존슨앤드존슨메디칼)coreMOU signed for data-based arrhythmia diagnosis and treatment technology collaboration in August 2022. Initial MOU for arrhythmia diagnosis and treatment technology was signed in April 2021.
- KHAIM (주)카임)coreJoint venture company established in 2022 with KUMC Healthcare Technology Holdings (고려대학교 의료기술지주) for healthcare technology development and commercialization.
- Yuhan Corporation (유한양행)coreYuhan Corporation holds domestic Korean distribution rights for MEMO Patch under licensing agreement signed June 2022. Yuhan also provided strategic investment of 50 billion KRW in 2020 and is a key investor.
Scale indicators6 records
Recent moves8 records
Expansion highlights7 records
HUINNO competitors and assessment
Company assessmentDirect peers
- iRhythm Technologies: iRhythm's Zio long-term ambulatory ECG patch and AI-based arrhythmia detection platform directly compete with Huinno's MEMO Patch 2 / MEMO Care solution; both target the same cardiology workflow of extended-duration patch monitoring replacing traditional Holter.
- Masimo: Masimo's Patient SafetyNet and rainbow SET pulse oximetry / continuous monitoring platform competes directly with Huinno's MEMO Cue + MEMO Band combination for multi-parameter bedside and ambulatory monitoring in hospital general wards.
- AliveCor: AliveCor's KardiaMobile 6L and KardiaNet AI ECG service compete in consumer and clinical-grade AI ECG interpretation — closely paralleling Huinno's MEMO Watch and MEMO AI ECG classification offering.
Emerging players
- SmartCardia: SmartCardia's AI-driven wearable patch for continuous ECG and vital signs monitoring is a direct emerging competitor to Huinno's MEMO Patch M, focused on similar in-patient and remote monitoring use cases.
- Vivalink: Vivalink provides wearable ECG and remote patient monitoring platform technology that overlaps with Huinno's MEMO ecosystem; focuses on ambulatory cardiac and RPM data infrastructure.
Broad incumbents
- GE HealthCare: GE HealthCare's patient monitoring portfolio (incl. EK-Pro, ApexPro) competes with MEMO Cue in-hospital telemetry; ICU and general-ward cardiac monitoring is a core GE franchise, making it the most established incumbent Huinno must displace.
- Boston Scientific (Preventice BodyGuardian): Boston Scientific acquired Preventice Solutions whose BodyGuardian Heart remote cardiac monitor competes with Huinno's MEMO Patch in ambulatory arrhythmia detection; large medtech with global sales infrastructure.
- Philips (BioTelemetry / Cardiac Monitoring): Philips acquired BioTelemetry to offer MCOT ambulatory ECG and IntelliVue in-hospital patient monitoring — overlapping with Huinno's MEMO Care (ambulatory) and MEMO Cue (in-patient telemetry) product lines but as part of a much larger portfolio.
- Hillrom / Baxter (Welch Allyn, Cardio Express): Hillrom (now part of Baxter) provides in-hospital vital signs and cardiac monitoring solutions that overlap with MEMO Cue; broad incumbent with established hospital purchasing relationships.
Regional players
- Wellysis: Wellysis is a Korean digital health company with FDA-cleared S-Patch ECG wearable and AI arrhythmia analysis — a domestic Korean peer to Huinno with overlapping product positioning and similar regulatory strategy targeting the US market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
HUINNO social profiles
Digital presenceHUINNO compliance and trust
Trust signalCompliance3 records
HUINNO financial estimates
Financial estimateRevenue estimate
Valuation estimate
HUINNO leadership team
Management profileNumber of profiles
Profiles7 records
HUINNO subsidiaries and ownership
Company hierarchySubsidiaries2 records
HUINNO funding detail
Funding detailFunding overview
Funding rounds5 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HUINNO M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HUINNO
What does HUINNO do?
HUINNO develops and sells AI-powered cardiac monitoring solutions that combine wearable biosignal sensors with cloud-based AI analytics to enable continuous in-hospital patient monitoring (MEMO Cue) and extended ambulatory ECG monitoring (MEMO Care). The integrated stack includes FDA 510(k)-cleared and CE-certified wearable ECG/respiration devices (MEMO Patch M, MEMO Patch 2, MEMO Watch, MEMO Band), web-based central monitoring and ECG analysis software, and an award-winning arrhythmia detection algorithm, sold primarily to hospitals and cardiology departments.
Is HUINNO a public or private company?
HUINNO is a private company. It is classified as venture growth investor backed and is currently operating.
When was HUINNO founded?
HUINNO was founded in 2014. It employs 51 to 100 people.
Where is HUINNO based?
HUINNO is headquartered in Seoul, South Korea, in the Asia region.
How does HUINNO make money?
Three revenue lines are on record. Wearable Medical Device Sales are the primary driver. The others are software as a Service (SaaS) - Remote Patient Monitoring and licensing and Distribution Agreements.
Who are HUINNO's main competitors?
Direct peers on record are iRhythm Technologies, Masimo and AliveCor. Emerging players are SmartCardia and Vivalink. Broad incumbents are GE HealthCare, Boston Scientific (Preventice BodyGuardian), Philips (BioTelemetry / Cardiac Monitoring) and Hillrom / Baxter (Welch Allyn, Cardio Express). Wellysis is listed as a regional player.
Does HUINNO have an API?
No public API is recorded for HUINNO.
What industry is HUINNO in?
HUINNO's product category is Cardiac Monitoring Solutions. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders), with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its NAICS code is 334510 and its SIC code is 3845.